Status:
COMPLETED
Outcome of Use of a Novel Modulator of Oxidative Phosphorylation on Kidney Function in Patients With Progressive Chronic Kidney Disease
Lead Sponsor:
Neukidney Inc.
Conditions:
Chronic Kidney Disease (Stage 3-4)
Chronic Kidney Disease (Stages 4 and 5)
Eligibility:
All Genders
18+ years
Brief Summary
Outcome of use of a novel Modulator of Oxidative Phosphorylation on kidney function in patients with Chronic Kidney Disease
Detailed Description
QRX-3 ( Eseronate ) is a formulated drug designed to supply and optimize NAD+ mitochondrial availability in order to target the loss of nephrons via renal fibrosis and tubular senescence of the kidney...
Eligibility Criteria
Inclusion
- Patient with Chronic kidney disease
- Estimated Glomerular function by MDRD of less than 60mls/min
- Patients with declining renal function ( as measured by eGFR by MDRD )
- Rate of decline of eGFR over the last one year of less than 20%
- Negative Serology markers for CKD etiology
- Provider perceived adherence to study follow up
Exclusion
- • Rapid rate of decline in kidney function of \> 20 % over last one year
- Symptomatic renal failure
- Presence of any suspected Acute renal failure superimposed
- Presence of cast , hematuria, or abnormal urinalysis outside of simple UTI
- No known reversible cause of renal decline
Key Trial Info
Start Date :
May 20 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 20 2022
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT07150338
Start Date
May 20 2021
End Date
November 20 2022
Last Update
September 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Premier Kidney clinic
Pasadena, Texas, United States, 77504